The efficacy of off-label IL-5-modulating treatment in rare eosinophil-mediated diseases

• Oded Shamriz,
• Alon Y. Hershko,
• Aviv Talmon,
• Yaarit Ribak,
• Anat Scheiman Elazary,
• Liran Horev,
• Adeeb NaserEddin,
• Tzahi Neuman,
• Sheer Shabat,
• Abraham Zlotogorski,
• Yuval Tal

Affiliations

Oded Shamriz

Allergy and Clinical Immunology Unit, Department of Medicine, Jerusalem, Israel; The Lautenberg Center for Immunology and Cancer Research, Institute of Medical Research Israel-Canada, Hebrew University-Hadassah Medical School, Jerusalem, Israel

Alon Y. Hershko

Allergy and Clinical Immunology Unit, Department of Medicine, Jerusalem, Israel; Corresponding author. Israeli Association of Allergy and Clinical Immunology, Department of Medicine C, Hadassah-Hebrew University Medical Center, Ein Kerem, 91120, Jerusalem, Israel.

Aviv Talmon

Allergy and Clinical Immunology Unit, Department of Medicine, Jerusalem, Israel

Yaarit Ribak

Allergy and Clinical Immunology Unit, Department of Medicine, Jerusalem, Israel

Anat Scheiman Elazary

Rheumatology Unit, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, Israel

Liran Horev

Department of Dermatology, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, Israel

Adeeb NaserEddin

Allergy and Clinical Immunology Unit, Department of Medicine, Jerusalem, Israel; Department of Bone Marrow Transplantation and Cancer Immunotherapy, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, Israel

Tzahi Neuman

Department of Pathology, Hadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, Israel

Sheer Shabat

Faculty of Medicine, The Hebrew University, Jerusalem, Israel

Abraham Zlotogorski

Department of Dermatology, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, Israel

Yuval Tal

Allergy and Clinical Immunology Unit, Department of Medicine, Jerusalem, Israel